AA
INSY

Antipodean Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Antipodean Advisors’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-305,294
Closed -$3.95M – 22
2016
Q2 		$3.95M Sell
305,294
-37,000
-11% -$539K 2.39% 15
2016
Q1 		$5.47M Sell
342,294
-227,991
-40% -$4.33M 2.48% 12
2015
Q4 		$16.3M Buy
+570,285
New +$15.8M 2.38% 12

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Antipodean Advisors's INSY Position: Q3 2016 in Review

Antipodean Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q3 2016, closing a stake of 305,294 shares — an estimated $3.95M sold.

Antipodean Advisors first reported a position in INSY in Q4 2015 and held it in 3 quarters. The position peaked at $16.3M in Q4 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q3 2016.

  • Antipodean Advisors reported no remaining Insys Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Antipodean Advisors sold 305,294 Insys Therapeutics, Inc. shares in Q3 2016, an estimated $3.95M.
  • Antipodean Advisors first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 3 quarters.
  • Antipodean Advisors's Insys Therapeutics, Inc. position peaked at $16.3M in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2016.

Based on Antipodean Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.